BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

The Conversation (0)
Exceptional silver and cobalt assays from seaweed

Exceptional silver and cobalt assays from seaweed

BPH Global (BP8:AU) has announced Exceptional silver and cobalt assays from seaweed

Download the PDF here.

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

BPH Global (BP8:AU) has announced Quarterly Activities/Appendix 4C Cash Flow Report

Download the PDF here.

Completion of Indonesian Seaweed Joint Venture Transaction

Completion of Indonesian Seaweed Joint Venture Transaction

BPH Global (BP8:AU) has announced Completion of Indonesian Seaweed Joint Venture Transaction

Download the PDF here.

BPH Global receives funding commitment of A$100,000

BPH Global receives funding commitment of A$100,000

BPH Global (BP8:AU) has announced BPH Global receives funding commitment of A$100,000

Download the PDF here.

Invion Limited

Successful Completion of Placement to Accelerate Clinical Programs

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce that it has successfully completed a new share placement (Placement) to raise $2.0 million to advance research and development in Photosoft™ as a potential treatment for a range of cancers.

Keep reading...Show less
Recce Pharmaceuticals

Japan Patent Allowance for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041.

Keep reading...Show less
Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less

Latest Press Releases

Related News

×